Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
Fujiwara K, Kondo T, Fujimoto K, Yumita S, Ogawa K, Ishino T, Nakagawa M, Iwanaga T, Tsuchiya S, Koroki K, Kanzaki H, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Ogasawara S, Nakamoto S, Chiba T, Koizumi J, Kato J, Kato N. Fujiwara K, et al. Among authors: nakamoto s. J Gastroenterol. 2024 Jun;59(6):515-525. doi: 10.1007/s00535-024-02097-9. Epub 2024 Apr 7. J Gastroenterol. 2024. PMID: 38583112 Free PMC article.
Ectopic Breast Cancer Arising within an Axillary Lymph Node.
Toshima K, Shien T, Nishimura MF, Suzuki Y, Nakamoto S, Uno M, Yoshioka R, Tsukioki T, Takahashi Y, Iwamoto T, Iwatani T, Yanai H. Toshima K, et al. Among authors: nakamoto s. Acta Med Okayama. 2024 Feb;78(1):89-93. doi: 10.18926/AMO/66676. Acta Med Okayama. 2024. PMID: 38419320 Free article.
[A MULTICENTER CLINICAL SURVEY ABOUT THE PREVALENCE OF JAPANESE CYPRESS POLLINOSIS AND THE EFFICACY OF SUBLINGUAL IMMUNOTHERAPY WITH JAPANESE CEDAR POLLEN EXTRACT DURING JAPANESE CYPRESS POLLEN DISPERSAL PERIOD].
Oka A, Yuta A, Okawa Y, Masuno S, Tsunoda T, Takahara E, Terada A, Kanai K, Nagakura H, Mimura H, Arao H, Ueyama S, Ueyama A, Tokuda R, Bamba H, Nakazato H, Nakazato M, Amesara R, Nakai S, Araki S, Sakaida M, Tokuriki M, Hama T, Chiba M, Ikeda H, Togawa A, Tsuzuki H, Hyo Y, Niitsu S, Ohkawa C, Nakamoto S, Takeo T, Kumanomidou H, Kanai K, Kitamura H, Sugiura R, Okano M. Oka A, et al. Among authors: nakamoto s. Arerugi. 2023;72(9):1138-1146. doi: 10.15036/arerugi.72.1138. Arerugi. 2023. PMID: 37967960 Japanese.
Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study.
Nakamoto S, Shien T, Itoh M, Yamamoto Y, Ohsumi S, Yoshitomi S, Hikino H, Miyoshi K, Notsu A, Taira N, Doihara H, Ikeda M. Nakamoto S, et al. Clin Exp Med. 2023 Dec;23(8):5129-5138. doi: 10.1007/s10238-023-01230-x. Epub 2023 Oct 30. Clin Exp Med. 2023. PMID: 37904008
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y, Seko Y, Moriguchi M, Watanabe S, Shiko Y, Takatsuka H, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Inaba Y, Ikeda M, Okabe S, Morimoto N, Itoh Y, Nakamura K, Ito K, Azemoto R, Atsukawa M, Itobayashi E, Kato N. Kobayashi K, et al. Among authors: nakamoto s. Clin Cancer Res. 2023 Dec 1;29(23):4760-4769. doi: 10.1158/1078-0432.CCR-23-1462. Clin Cancer Res. 2023. PMID: 37796614
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury.
Kondo T, Fujimoto K, Fujiwara K, Yumita S, Ishino T, Ogawa K, Nakagawa M, Iwanaga T, Koroki K, Kanzaki H, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Ogasawara S, Nakamoto S, Chiba T, Kato J, Fujiwara K, Kato N. Kondo T, et al. Among authors: nakamoto s. Sci Rep. 2023 Aug 28;13(1):14043. doi: 10.1038/s41598-023-41425-6. Sci Rep. 2023. PMID: 37640752 Free PMC article.
470 results